The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

Marcin F. Osuchowski, Martin S. Winkler, Tomasz Skirecki, Sara Cajander, Manu Shankar-Hari, Gunnar Lachmann, Guillaume Monneret, Fabienne Venet, Michael Bauer, Frank M. Brunkhorst, Sebastian Weis, Alberto Garcia-Salido, Matthijs Kox, Jean Marc Cavaillon, Florian Uhle, Markus A. Weigand, Stefanie B. Flohé, W. Joost Wiersinga, Raquel Almansa, Amanda de la FuenteIgnacio Martin-Loeches, Christian Meisel, Thibaud Spinetti, Joerg C. Schefold, Catia Cilloniz, Antoni Torres, Evangelos J. Giamarellos-Bourboulis, Ricard Ferrer, Massimo Girardis, Andrea Cossarizza, Mihai G. Netea, Tom van der Poll, Jesús F. Bermejo-Martín, Ignacio Rubio

Producción científica: Artículo CientíficoArtículo de revisiónrevisión exhaustiva

314 Citas (Scopus)

Resumen

The zoonotic SARS-CoV-2 virus that causes COVID-19 continues to spread worldwide, with devastating consequences. While the medical community has gained insight into the epidemiology of COVID-19, important questions remain about the clinical complexities and underlying mechanisms of disease phenotypes. Severe COVID-19 most commonly involves respiratory manifestations, although other systems are also affected, and acute disease is often followed by protracted complications. Such complex manifestations suggest that SARS-CoV-2 dysregulates the host response, triggering wide-ranging immuno-inflammatory, thrombotic, and parenchymal derangements. We review the intricacies of COVID-19 pathophysiology, its various phenotypes, and the anti-SARS-CoV-2 host response at the humoral and cellular levels. Some similarities exist between COVID-19 and respiratory failure of other origins, but evidence for many distinctive mechanistic features indicates that COVID-19 constitutes a new disease entity, with emerging data suggesting involvement of an endotheliopathy-centred pathophysiology. Further research, combining basic and clinical studies, is needed to advance understanding of pathophysiological mechanisms and to characterise immuno-inflammatory derangements across the range of phenotypes to enable optimum care for patients with COVID-19.

Idioma originalInglés estadounidense
Páginas (desde-hasta)622-642
-21
PublicaciónThe Lancet Respiratory Medicine
Volumen9
N.º6
DOI
EstadoIndizado - jun. 2021
Publicado de forma externa

Nota bibliográfica

Publisher Copyright:
© 2021 Elsevier Ltd

Huella

Profundice en los temas de investigación de 'The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity'. En conjunto forman una huella única.

Citar esto